CIAVARELLA, ALESSANDRO
CIAVARELLA, ALESSANDRO
Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti
Clinical and Laboratory Presentation and Underlying Mechanism in Patients with Low VWF
2024 O. Seidizadeh, A. Ciavarella, L. Baronciani, F. Boggio, F. Ballardini, G. Cozzi, P. Colpani, M.T. Pagliari, C. Novembrino, S.M. Siboni, F. Peyvandi
Type 2M/2A von Willebrand disease: a shared phenotype between type 2M and 2A
2024 O. Seidizadeh, L. Mollica, S. Zambarbieri, L. Baronciani, A. Cairo, P. Colpani, G. Cozzi, M.T. Pagliari, A. Ciavarella, S.M. Siboni, F. Peyvandi
Ultrasound evaluation of hemophilic arthropathy: a proposal of definitions in a changing landscape
2024 R. Gualtierotti, L.P. Solimeno, F. Peyvandi, A. Giachi, S. Arcudi, A. Ciavarella, S.M. Siboni
Assessing joint health in haemophilia patients: The combined value of physical examination and ultrasound imaging
2024 R. Gualtierotti, A. Giachi, A. Truma, S. Arcudi, A. Ciavarella, P. Bucciarelli, D. Consonni, E. Boccalandro, V. Begnozzi, L.P. Solimeno, S.M. Siboni, F. Peyvandi
Safety and efficacy of combined dual antiplatelet therapy and factor VIII prophylaxis in patients with haemophilia A after acute coronary syndrome
2024 P. Agosti, S.M. Siboni, A. Ciavarella, S. Arcudi, F. Boggio, R. Gualtierotti, F. Peyvandi
Variant p.Tyr1584Cys: a frequent von Willebrand factor variant in search of von Willebrand disease
2024 O. Seidizadeh, L. Baronciani, P. Colpani, G. Cozzi, A. Ciavarella, S.M. Siboni, F. Peyvandi
Characterization of Immunogenicity and Safety of COVID-19 mRNA-1273 in HIV-Positive Italian Patients with Hemophilia: A Prospective Single-Center Cohort Study
2023 C. Suffritti, R. Gualtierotti, S. Arcudi, A. Ciavarella, C. Novembrino, A. Lecchi, S. La Marca, L. Padovan, E. Scalambrino, M. Clerici, P. Bono, F. Ceriotti, A. Muscatello, S. Maria Siboni, F. Peyvandi
Hemorrhagic and thrombotic adverse events associated with emicizumab and extended half-life factor VIII replacement drugs: EudraVigilance data of 2021
2023 M. Abbattista, A. Ciavarella, D. Noone, F. Peyvandi
Residual burden of liver disease after HCV clearance in hemophilia: a word of caution in the era of gene therapy
2023 V. LA MURA, N. Bitto, C. Capelli, C. Caputo, S. Maria Siboni, S. Arcudi, A. Ciavarella, R. Gualtierotti, A.L. Fracanzani, A. Sangiovanni, F. Peyvandi
A retrospective study on the use of low-molecular-weight heparin for prevention of pregnancy-related recurrent venous thromboembolism and obstetrical complications
2023 M. Abbattista, M. Capecchi, F. Gianniello, A. Artoni, P. Bucciarelli, A. Ciavarella, F. Peyvandi, I. Martinelli
Anti-emicizumab antibodies do not cross-react with mim8 in vitro
2023 C. Valsecchi, R. Gualtierotti, S. Arcudi, A. Ciavarella, S.M. Siboni, L. Schiavone, M. Beeg, M. Gobbi, F. Peyvandi
Updates on Novel Non-Replacement Drugs for Hemophilia
2022 R. Gualtierotti, S. Pasca, A. Ciavarella, S. Arcudi, A. Giachi, I. Garagiola, C. Suffritti, S.M. Siboni, F. Peyvandi
Anticoagulant Therapy in Patients with Antiphospholipid Syndrome
2022 M. Capecchi, M. Abbattista, A. Ciavarella, M. Uhr, C. Novembrino, I. Martinelli
Reduced FVIII recovery associated with anti-FVIII PEG antibodies after BNT162b2 SARS-CoV-2 vaccination
2022 C. Valsecchi, R. Gualtierotti, S. Arcudi, A. Ciavarella, L. Schiavone, C. Novembrino, S. Maria Siboni, P. Mannuccio Mannucci, F. Payvandi
Increasing dosages of low-molecular-weight heparin in hospitalized patients with Covid-19
2021 I. Martinelli, A. Ciavarella, M. Abbattista, S. Aliberti, V. De Zan, C. Folli, M. Panigada, A. Gori, A. Artoni, A.M. Ierardi, G. Carrafiello, V. Monzani, G. Grasselli, F. Blasi, F. Peyvandi
Risk factors for mortality in hospitalized patients with COVID-19: a study in Milan, Italy
2020 M. Abbattista, A. Ciavarella, M. Capecchi, F. Tantardini, A. Gramegna, R. Lombardi, N. Scaramellini, F. Peyvandi, I. Martinelli
Hemostasis in pregnant women with COVID-19
2020 A. Ciavarella, R. Erra, M. Abbattista, E. Iurlaro, M. Boscolo-Anzoletti, M.W. Ossola, F. Mosca, E. Ferrazzi, F. Peyvandi, I. Martinelli